Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979661694> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2979661694 endingPage "S1614" @default.
- W2979661694 startingPage "S1614" @default.
- W2979661694 abstract "INTRODUCTION: Hepatic Steatosis is associated with cardiovascular disease independently of classic risk factors. Hepatocytes secrete proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) which in turn inhibits the uptake of low-density lipo-proteins by targeting the receptor for degradation and possibly lipogenesis. Anti-PCSK9 drugs reduce LDL-cholesterol but it is unclear how it affects the liver function in patients with underlying steatosis. AIM: To evaluate the efficacy and safety of PCSK9 inhibitors in patients with Fatty Liver disease. METHODS: A retrospective chart review study was done from September 2015 to January 2018 to include patients currently prescribed PCSK9 inhibitors who had an ICD code of hepatic steatosis or fatty liver disease. Blood AST (aspartate aminotransferase), ALT (alanine aminotransferase), Triglycerides, Cholesterol and HBA1c were charted of patients who were started on this medication and were followed after interval of 12 months while on the medication. This was compared to a control of patients who were not on PCSK9 but did have underlying diagnosis of fatty liver disease. RESULTS: A total of 37 patients on PCSK9 were identified having the ICD 9 and 10 code for fatty liver disease. A random control of 73 patients with the same ICD9/10 code were identified. The mean age of all the patients was 63 (32-90 years), 36% male and 64% female. The mean ALT in the study group after 12 months of PCSK9 therapy was 51 which was not statistically different from the control group ( P = 0.05). The average AST value was 43 in the group that was studied and was not statistically significant ( P = 0.09). Mean Triglyceride value was 180 ( P = 0.87) and mean cholesterol was 143 ( P < 0.01). This shows that the drug does significantly reduce the cholesterol values. CONCLUSION: PCSK9 may not have a detrimental effect on the liver profile as observed in our study. There was no significant difference in the liver function test after initiation of the drug. These drugs may serve as alternative agents for those who have experienced or are at risk of hepatic injury." @default.
- W2979661694 created "2019-10-18" @default.
- W2979661694 creator A5034263662 @default.
- W2979661694 creator A5034641084 @default.
- W2979661694 creator A5067624582 @default.
- W2979661694 creator A5085134340 @default.
- W2979661694 creator A5087504379 @default.
- W2979661694 date "2019-10-01" @default.
- W2979661694 modified "2023-09-23" @default.
- W2979661694 title "2974 PCSK9 Inhibitors Do Not Worsen Liver Function Tests in Patients With Hepatic Steatosis" @default.
- W2979661694 doi "https://doi.org/10.14309/01.ajg.0000601428.34930.4d" @default.
- W2979661694 hasPublicationYear "2019" @default.
- W2979661694 type Work @default.
- W2979661694 sameAs 2979661694 @default.
- W2979661694 citedByCount "0" @default.
- W2979661694 crossrefType "journal-article" @default.
- W2979661694 hasAuthorship W2979661694A5034263662 @default.
- W2979661694 hasAuthorship W2979661694A5034641084 @default.
- W2979661694 hasAuthorship W2979661694A5067624582 @default.
- W2979661694 hasAuthorship W2979661694A5085134340 @default.
- W2979661694 hasAuthorship W2979661694A5087504379 @default.
- W2979661694 hasConcept C126322002 @default.
- W2979661694 hasConcept C134018914 @default.
- W2979661694 hasConcept C2776175330 @default.
- W2979661694 hasConcept C2777075537 @default.
- W2979661694 hasConcept C2778163477 @default.
- W2979661694 hasConcept C2778772119 @default.
- W2979661694 hasConcept C2778849439 @default.
- W2979661694 hasConcept C2778913445 @default.
- W2979661694 hasConcept C2779134260 @default.
- W2979661694 hasConcept C2780072125 @default.
- W2979661694 hasConcept C2780948078 @default.
- W2979661694 hasConcept C2992208098 @default.
- W2979661694 hasConcept C43554185 @default.
- W2979661694 hasConcept C512861765 @default.
- W2979661694 hasConcept C71924100 @default.
- W2979661694 hasConcept C90924648 @default.
- W2979661694 hasConceptScore W2979661694C126322002 @default.
- W2979661694 hasConceptScore W2979661694C134018914 @default.
- W2979661694 hasConceptScore W2979661694C2776175330 @default.
- W2979661694 hasConceptScore W2979661694C2777075537 @default.
- W2979661694 hasConceptScore W2979661694C2778163477 @default.
- W2979661694 hasConceptScore W2979661694C2778772119 @default.
- W2979661694 hasConceptScore W2979661694C2778849439 @default.
- W2979661694 hasConceptScore W2979661694C2778913445 @default.
- W2979661694 hasConceptScore W2979661694C2779134260 @default.
- W2979661694 hasConceptScore W2979661694C2780072125 @default.
- W2979661694 hasConceptScore W2979661694C2780948078 @default.
- W2979661694 hasConceptScore W2979661694C2992208098 @default.
- W2979661694 hasConceptScore W2979661694C43554185 @default.
- W2979661694 hasConceptScore W2979661694C512861765 @default.
- W2979661694 hasConceptScore W2979661694C71924100 @default.
- W2979661694 hasConceptScore W2979661694C90924648 @default.
- W2979661694 hasIssue "1" @default.
- W2979661694 hasLocation W29796616941 @default.
- W2979661694 hasOpenAccess W2979661694 @default.
- W2979661694 hasPrimaryLocation W29796616941 @default.
- W2979661694 hasRelatedWork W1964078018 @default.
- W2979661694 hasRelatedWork W2035484352 @default.
- W2979661694 hasRelatedWork W2055270596 @default.
- W2979661694 hasRelatedWork W2103809310 @default.
- W2979661694 hasRelatedWork W2376999400 @default.
- W2979661694 hasRelatedWork W2379565763 @default.
- W2979661694 hasRelatedWork W2386924618 @default.
- W2979661694 hasRelatedWork W2388036281 @default.
- W2979661694 hasRelatedWork W2938328462 @default.
- W2979661694 hasRelatedWork W2979661694 @default.
- W2979661694 hasVolume "114" @default.
- W2979661694 isParatext "false" @default.
- W2979661694 isRetracted "false" @default.
- W2979661694 magId "2979661694" @default.
- W2979661694 workType "article" @default.